RankAlpha logo
Back to Rankings

RNAZ

TransCode TherapeuticsF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
View Chart
+
Peers tracked
8
U.S. public peers
Grade Position
Below peers
vs peer average
RNAZ vs peer average
42/100
RNAZ vs. peer average (F vs. D)
Grade spread
C 1 · D 2 · F 5
Graded peers loaded
Coverage
8 graded
100% of tracked

Peer overview

APRE is the first available peer comparator.

Same sector: Pharmaceuticals, Biotechnology & Life Sciences · Cap $8.28M

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerAPREAprea Therapeutics
RNAZ
TransCode Therapeutics
APRE
Aprea Therapeutics
Grade
F
F
Momentum
8
10
Value
58
57
Sentiment
-
-
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Open Side-by-Side ComparisonCompare all

Grade position vs APRE

RNAZ / APRE
Grade Position
Below peers
RNAZ vs. peer average (F vs. D)
42/100
Momentum
8
APRE
Value
58
RNAZ
Sentiment
-
-

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs RNAZ
1
APRE
Aprea Therapeutics Inc Common
F
20/100
Even
2
QNRX
Quoin Pharmaceuticals. Ltd ADR
C
60/100
-2
3
BRTX
BioRestorative Therapies Inc Common
F
20/100
Even
4
ASBP
Aspire Biopharma Holdings Inc Common
F
20/100
Even
5
CNSP
CNS Pharmaceuticals Inc Common
F
20/100
Even
APRE is the first peer returned for this comparison set.